Company news

Rhythm Biosciences Limited news in 2024

Rhythm Biosciences Limited's news releases, calls and decks from 2024, newest first.

View company

Completion of Genetype Risk Assessment Portfolio Acquisition

December 23, 2024

RHY Acquires Genetype Genetic Risk Assessment Business

December 22, 2024

Pause in Trading

December 20, 2024

Market Update - All End of CY24 Milestones Attained

December 17, 2024

Strong Demand in Share Placement to Raise $3.5 million

November 18, 2024

Receipt of Research & Development Tax Incentive

November 6, 2024

2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms

October 6, 2024

Board Renewal / Composition Update

September 29, 2024

Platform Expansion - Gastric Cancer Diagnostic Test Update

September 23, 2024

Product and Market Update - Phase 2 Milestone

August 27, 2024

Jun 24 Quarterly Activities Report and Appendix 4C

July 28, 2024

Mar24 Quarterly Activities Report and Appendix 4C

April 29, 2024

Dr David Atkins appointed Chief Executive Officer of Rhythm

April 24, 2024

Rhythm Maintains ISO Certification

April 22, 2024

Close of Rights Issue

March 20, 2024

Internationally Renowned Clinical Advisory Board Established

March 18, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Half Yearly Report and Accounts

February 28, 2024

Prospectus - 2024 Non-Renounceable Rights Issue

February 18, 2024

Rights Issue Offer to Raise Up To $6.6 million

February 8, 2024

Quarterly Activities Report and Appendix 4C - Dec23

January 30, 2024

Decks in 2024